Noucor is a pharmaceutical company based in Barcelona, established in December 2021 as a result of a spin-out from Uriach. Backed by MCH Private Equity, Noucor operates in over 100 markets worldwide, employing a B2B approach. The company focuses on developing New Chemical Entities (NCEs), with Rupatadine being its flagship product, alongside a range of Generic (GX) products. Noucor is vertically integrated in most of its offerings, possessing both Active Pharmaceutical Ingredient (API) capabilities and pharmaceutical manufacturing plants. The company's R&D pipeline includes GX products and VAM, which is currently undergoing a pilot Phase III trial involving 300 patients.

Services include:
- Development of New Chemical Entities (NCEs)
- Manufacturing of Generic (GX) products
- Production of Active Pharmaceutical Ingredients (APIs)
- Pharmaceutical manufacturing
- Research and development for pharmaceutical products

Noucor is committed to delivering innovative pharmaceutical solutions and maintaining a robust presence in the global market. For more information, please visit noucor.com.